These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10745259)

  • 1. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
    Khoury H; Adkins D; Brown R; Trinkaus K; Vij R; Miller G; Goodnough LT; DiPersio J
    Bone Marrow Transplant; 2000 Apr; 25(7):737-43. PubMed ID: 10745259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
    Al Beihany A; Al Omar H; Sahovic E; Chaudhri N; Al Mohareb F; Al Sharif F; Al Zahrani H; Al Shanqeeti A; Seth P; Zaidi S; Morshed M; Al Anazi K; Mohamed G; Gyger M; Aljurf M
    Bone Marrow Transplant; 2008 Feb; 41(3):287-91. PubMed ID: 17982501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S; Rodriguez M; Lafuente A; Mateos P; Mehta J; Singhal S; Saso R; Tait D; Treleaven JG; Powles RL
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for high-dose methylprednisolone in the treatment of hepatic regimen-related toxicity?
    Hennenfent KL; Augustin KM; Dipersio JF; Khoury H
    Bone Marrow Transplant; 2006 Jan; 37(2):229. PubMed ID: 16284616
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial.
    Volpin R; Angeli P; Galioto A; Fasolato S; Neri D; Barbazza F; Merenda R; Del Piccolo F; Strazzabosco M; Casagrande F; Feltracco P; Sticca A; Merkel C; Gerunda G; Gatta A
    Liver Transpl; 2002 Jun; 8(6):527-34. PubMed ID: 12037783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
    Leahey AM; Bunin NJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
    Toh HC; McAfee SL; Sackstein R; Cox BF; Colby C; Spitzer TR
    Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
    Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
    Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
    Myers KC; Dandoy C; El-Bietar J; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):379-81. PubMed ID: 25300869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease.
    Aziz A; Aziz S; Li DS; Murphy L; Leone N; Kennedy M; Dhillon S; Van Thiel DH
    J Viral Hepat; 2006 Apr; 13(4):217-21. PubMed ID: 16611186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.
    Myers KC; Lawrence J; Marsh RA; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):500-3. PubMed ID: 23211838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
    Chan P
    Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management.
    Iqbal M; Creger RJ; Fox RM; Cooper BW; Jacobs G; Stellato TA; Lazarus HM
    Bone Marrow Transplant; 1996 Apr; 17(4):655-62. PubMed ID: 8722371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.